Oleh Taratula et al. developed dual targeting NLCs loaded with an anticancer drug (Doxorubicin or Paclitaxel) to induce cell death and siRNA to target MRP1 mRNA and BCL2 mRNA to suppress pump and nonpump cellular resistance in lung cancer cells respectively and overcome resistance. This evidence concerns the gene ABCC1 and lung carcinoma.